SCAAR: CHANGES IN DRUG ELUTING STENT USE AND INSTENT-RESTENOSIS RATES FROM 2002 TO 2012  by Varenhorst, Christoph et al.
TCT@ACC-i2: The Interventional Learning Pathway
A1902
JACC April 1, 2014
Volume 63, Issue 12
scAAr: chAnges in Drug eluting stent use AnD instent-restenosis rAtes froM 2002 to 
2012
Poster Contributions
Hall C
Monday, March 31, 2014, 9:45 a.m.-10:30 p.m.
Session Title: Coronary Intervention - Stents
Abstract Category: 36. TCT@ACC-i2: ACS/AMI/Hemodynamics and Pharmacology
Presentation Number: 2111-302
Authors: Christoph Varenhorst, Giovanna Sarno, Kristina Hambraeus, Oskar Angerås, Göran Olivecrona, Bo Lagerqvist, Stefan James, Dept of 
Medical Sciences, Cardiology and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden
background: Primarily because a concern about stent thrombosis, drug eluting stent (DES) use decreased markedly in 2006-2007. The aim of this 
study was to describe yearly restenosis rates according to DES use in Sweden. 
Methods: We calculated yearly restenosis rates and DES use in SCAAR (Swedish Coronary Angiography and Angioplasty Registry) from 2002 to 
2012 in Sweden and individual hospitals. All percutaneous coronary intervention (PCI) procedures between January 2002 and December 2012 were 
included (n=162,937). Restenosis was recorded in SCAAR in all previously treated lesions.
results: The proportion of PCI-treated patients receiving DES increased from 8.7 % in 2002 to 63.9 % in December 2005 to rapidly decline to 
12.9 % in July 2007. In-stent restenosis (ISR) rates peaked in 2008 with 6.0 %. In the end of 2012, DES were used in 83 % of all PCIs and ISR 
gradually declined to 4.9 %. DES use showed a large variation between hospitals. During the observation period: hospitals with high restenosis rates 
coincided with low DES use.
conclusion:  DES penetration rates are steadily increasing in Sweden since 2007 and the restenosis rates are decreasing. This may have 
implications on the overall health care consumption.
